Explore

Rapid Read Rapid Read
FDA Considers Easing Restrictions on Peptide Injections Amid Safety Concerns

FDA Considers Easing Restrictions on Peptide Injections Amid Safety Concerns

The Food and Drug Administration (FDA) is evaluating the possibility of allowing compounding pharmacies to produce seven peptides that are currently restricted due to safety concerns. This move comes as peptides gain popularity for their purported wellness and anti-aging benefits, despite many claims remaining untested. Health Secretary Robert F. Kennedy Jr. has expressed support for making peptides more accessible, citing the need to curb the illicit market that has emerged due to current restrictions. The FDA's advisory panel on pharmacy compounding is set to discuss the potential use of these peptides for various conditions, including ulcerative colitis and obesity, in a meeting scheduled for late July. The agency has previously categorized certain peptides as too risky for compounding, but the growing demand and unauthorized sales have prompted a reevaluation.
AP News AP News
FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures

FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures

Federal health officials will meet this summer to consider easing restrictions on a controversial group of drugs popular with followers of Robert F. Kennedy Jr.'s Make America Healthy Again movement
Rapid Read Rapid Read
FDA Considers Easing Restrictions on Unproven Peptides Amid RFK Jr.'s Advocacy

FDA Considers Easing Restrictions on Unproven Peptides Amid RFK Jr.'s Advocacy

The U.S. Food and Drug Administration (FDA) is set to hold a meeting this summer to discuss the potential easing of restrictions on several peptide injections. These peptides, which are unapproved therapies, have gained popularity among wellness influencers and celebrities for their purported benefits in muscle building, injury healing, and anti-aging. Health Secretary Robert F. Kennedy Jr. has been a vocal advocate for loosening these regulations, despite the lack of substantial research supporting the safety and efficacy of these peptides. The FDA plans to consult a panel of outside advisers to review seven specific peptides, including BPC-157, which is marketed for injury healing and inflammation reduction. The agency has indicated it will remove these peptides from a list of high-risk, unapproved drugs, potentially allowing them to be produced by pharmacies.
Rapid Read Rapid Read
FDA Considers Lifting Restrictions on Peptides Amid Wellness Trend

FDA Considers Lifting Restrictions on Peptides Amid Wellness Trend

The Food and Drug Administration (FDA) is evaluating the possibility of allowing compounding pharmacies to produce seven peptides that are currently restricted due to safety concerns. This move comes as peptides gain popularity for their purported wellness and anti-aging benefits. Health and Human Services Secretary Robert F. Kennedy Jr. has expressed support for making these peptides more accessible, citing their potential benefits for conditions such as ulcerative colitis, wound healing, and obesity. The FDA's advisory panel on pharmacy compounding is set to discuss these peptides in a meeting scheduled for late July. The agency's previous classification of certain peptides as 'Bulk Drug Substances that Raise Significant Safety Risks' has led to a black market for these substances.
Trendline Trendline
FDA Considers Easing Restrictions on Unproven Peptides Popular Among Wellness Influencers

FDA Considers Easing Restrictions on Unproven Peptides Popular Among Wellness Influencers

FDA Considers Easing Restrictions on Unproven Peptides Popular Among Wellness Influencers
Rapid Read Rapid Read
FDA Classifies Cough Drops Recall as Moderate Risk Due to Quality Concerns

FDA Classifies Cough Drops Recall as Moderate Risk Due to Quality Concerns

The U.S. Food and Drug Administration (FDA) has classified a nationwide recall of multiple cough drop products as a Class II recall, indicating a moderate risk to consumers. The recall, initiated on March 20, 2026, was prompted by an FDA inspection at an overseas manufacturing facility that revealed conditions potentially affecting product quality. The affected products, manufactured in China by Xiamen Kang Zhongyuan Biotechnology Co., Ltd., include various flavors and are distributed under several brand names such as Exchange Select and Caring Mill. These products are sold in packages ranging from 25 to 90 counts and have expiration dates in 2026. The FDA's classification suggests that while the likelihood of serious harm is low, the use of these products may cause temporary or medically reversible adverse health effects.
Trendline Trendline
PolyPid Presents Phase 3 Data on D-PLEX100's Sustained Antibiotic Release for Surgical Site Infections

PolyPid Presents Phase 3 Data on D-PLEX100's Sustained Antibiotic Release for Surgical Site Infections

PolyPid Presents Phase 3 Data on D-PLEX100's Sustained Antibiotic Release for Surgical Site Infections
Rapid Read Rapid Read
FDA Introduces New Draft Safety Guidelines to Accelerate Gene Therapy Development

FDA Introduces New Draft Safety Guidelines to Accelerate Gene Therapy Development

The U.S. Food and Drug Administration (FDA) has released new draft guidance aimed at standardizing safety evaluations for genome editing therapies. This initiative is part of the FDA's efforts to expedite the development of personalized gene therapies, particularly for ultra-rare diseases. The guidance focuses on next-generation sequencing techniques to identify unintended consequences of gene therapies. It builds on previous guidance from 2024 and includes recommendations for nonclinical studies related to investigational new drug and biologics license applications. The FDA is seeking public comments on this draft, which is part of a broader strategy to formalize the development of bespoke therapies, such as the first custom CRISPR therapy for a child with a rare metabolic condition.
Rapid Read Rapid Read
FDA Announces Nationwide Recall of Xanax Due to Dissolution Issue

FDA Announces Nationwide Recall of Xanax Due to Dissolution Issue

The U.S. Food and Drug Administration (FDA) has announced a nationwide recall of a specific lot of Xanax, a medication commonly prescribed for anxiety and panic disorders. The recall, initiated by Viatris Specialty LLC, a West Virginia-based distributor, is due to the product's failure to meet dissolution specifications, which could lead to adverse health effects. The recall affects Xanax XR extended-release tablets, specifically lot #8177156 with an expiration date of February 28, 2027. The FDA classified this as a Class II recall, indicating that the use of the product may cause temporary or medically reversible adverse health consequences. No adverse reactions have been reported so far.
Rapid Read Rapid Read
FDA Urges Over 2,200 Sponsors to Disclose Clinical Trial Results, Addresses Publication Bias

FDA Urges Over 2,200 Sponsors to Disclose Clinical Trial Results, Addresses Publication Bias

The U.S. Food and Drug Administration (FDA) has reminded more than 2,200 medical product companies and researchers to submit clinical trial results to ClinicalTrials.gov. The agency highlights the issue of publication bias, where negative trial results are often not disclosed, leading to a skewed perception of drug efficacy and safety. The FDA's initiative aims to ensure transparency and improve public access to clinical data. The agency has sent messages to companies and researchers to encourage voluntary compliance with reporting requirements, emphasizing the ethical obligation to disclose all trial outcomes.
Rapid Read Rapid Read
FDA Urges Over 2,200 Sponsors and Researchers to Disclose Clinical Trial Results

FDA Urges Over 2,200 Sponsors and Researchers to Disclose Clinical Trial Results

The U.S. Food and Drug Administration (FDA) has issued reminders to more than 2,200 medical product companies and researchers about their obligation to submit clinical trial results to ClinicalTrials.gov. This action addresses the issue of non-disclosure of trial results, which can lead to publication bias and a skewed perception of drug efficacy and safety. According to the FDA, nearly 30% of studies that should report results have not done so, particularly those involving FDA-regulated products. The agency's reminders aim to encourage voluntary compliance before considering further regulatory actions.
Rapid Read Rapid Read
FDA Urges Over 2,200 Sponsors and Researchers to Disclose Clinical Trial Results to Ensure Transparency

FDA Urges Over 2,200 Sponsors and Researchers to Disclose Clinical Trial Results to Ensure Transparency

The U.S. Food and Drug Administration (FDA) has issued reminders to more than 2,200 medical product companies and researchers to comply with the requirement to submit clinical trial results to ClinicalTrials.gov. This action addresses the issue of non-disclosure of trial results, which can lead to significant gaps in the public record and a publication bias that misrepresents the true outcomes of drug development. According to the FDA, 29.6% of studies that are likely subject to mandatory reporting have not submitted results. The agency's reminders, sent on March 30, 2026, aim to encourage voluntary compliance before considering further regulatory actions. The FDA emphasizes the ethical obligation of sponsors to disclose results, regardless of their impact on company share prices, to ensure that clinicians and researchers have access to comprehensive data.